The company has developed a controlled release drug delivery system (DDS), which is able to escape the P-gp (P-Glycoprotein) pump and bypass the extensive pre-systemic and liver first pass metabolism
The company's scientists have developed a novel, proprietary, versatile and biocompatible nanoemulsion technology for topical, transdermal and intranasal drug delivery (patent pending).
The development of molecular nano-capsules for targeting and delivering anti-cancer drugs to solid tumors by using a newly discovered exceptionally stable protein named SP1.
Company develops drug targeting and nano-encapsulation of drugs. These molecules are non-toxic with a wide range of applications including targeted drug delivery and on-site controlled drug release.
